Patriot National Announces Sale of Global HR Research
Apr 04, 2017 10:45 am UTC| Business
FORT LAUDERDALE, Fla., April 04, 2017 -- Patriot National, Inc. (NYSE:PN) (“Patriot National” or “the Company”), a leading provider of technology and outsourcing solutions to the insurance industry, today announced that...
Comstock Mining Announces 2017 Annual Meeting and Record Date
Apr 04, 2017 10:45 am UTC| Business
VIRGINIA CITY, Nev., April 04, 2017 -- Comstock Mining Inc. (“Comstock” or the “Company”) (NYSE MKT:LODE) announced today, that its 2017 Annual Meeting of Shareholders is scheduled for Thursday, June 1, 2017, at the...
Air Lease Corporation Activity Update for the First Quarter of 2017
Apr 04, 2017 10:31 am UTC| Business
LOS ANGELES, April 04, 2017 -- Today Air Lease Corporation (NYSE:AL) (“ALC”) announced an update on activity taking place in the first quarter of 2017: Business highlights: At the end of the first quarter of 2017,...
BMC Enhances Its Value-Added Offerings With Two Strategic Acquisitions
Apr 04, 2017 10:30 am UTC| Business
Texas Plywood Lumber Company, Inc. Strengthens BMC’s Millwork and Doors Production Abilities in the Dallas/Fort Worth MarketCode Plus Components Adds Truss Manufacturing Capabilities to BMC’s Washington, D.C. Market...
KLX Inc. Announces Filing of Extension for Form 10-K
Apr 04, 2017 10:30 am UTC| Business
WELLINGTON, Fla., April 04, 2017 -- KLX Inc. (the “Company”) (NASDAQ:KLXI), a leading distributor and value added service provider of aerospace fasteners and consumables, and a provider of services and products to the...
AmTrust Financial Services, Inc. Completes Annual Financial Restatements With Filing of Form 10-K
Apr 04, 2017 10:20 am UTC| Business
NEW YORK, April 04, 2017 -- AmTrust Financial Services, Inc. (Nasdaq:AFSI) (the “Company” or “AmTrust”) today filed its Form 10-K for the year ended December 31, 2016, including restated financial statements and related...
Apr 04, 2017 10:05 am UTC| Business
Orphan Drug designation allows RedHill to benefit from various development incentives to develop YELIVA® (ABC294640) for cholangiocarcinoma, as well as a seven-year marketing exclusivity period for the indication, if...